NewHydrogen, Inc. (NEWH) registered up to 275,000,000 shares of common stock for resale by GHS Investments, LLC. NewHydrogen receives no proceeds from GHS’s resales. The registered amount includes 980,713 commitment shares and up to 274,019,287 Purchase Shares. Under a 24-month financing agreement, NewHydrogen may direct purchases by GHS, subject to the agreement’s terms, and may receive up to $3,000,000 gross proceeds (approximately $2.8 million net) from those sales.
NewHydrogen is developing ThermoLoop™, a water-and-heat process for producing green hydrogen, with research at UC Santa Barbara. For the six months ended June 30, 2026, it reported no revenue, a $1,740,818 net loss and $1,460,435 used in operating activities. Its $182,530,308 accumulated deficit and recurring losses are among the factors raising substantial doubt about its ability to continue as a going concern. Management believes cash and investment balances will support development and general and administrative expenses for the next two months and estimates additional cash will be needed in the fourth quarter of 2026.
NewHydrogen, Inc. (NEWH) filed a Form S-1 registering up to 275,000,000 shares of common stock for resale by GHS Investments, LLC under an Equity Financing Agreement that permits purchases of up to $3,000,000 of stock over 24 months. NewHydrogen will not receive proceeds from GHS’s resale of these shares, but may receive up to $3 million in gross proceeds from sales of new shares to GHS at discounted market-based prices, subject to a 4.99% beneficial ownership cap and per-put size limits.
The company is a development-stage clean energy business focused on thermochemical green hydrogen technology and has no revenues to date, with an accumulated deficit of $182,530,308 through June 30, 2026 and a 2025 net loss of $2,846,943. Management and auditors highlight substantial doubt about the company’s ability to continue as a going concern. As of June 30, 2026, working capital was $788,355, and management expects to need additional capital by the fourth quarter of 2026, potentially relying on the GHS equity line.
NewHydrogen, Inc. (NEWH) entered into an Equity Financing Agreement with GHS Investments, LLC under which GHS has committed to provide up to $3,000,000 of funding through purchases of NewHydrogen common stock after a Form S-1 registration statement becomes effective. NewHydrogen may deliver put notices for share sales, subject to limits tied to recent trading volume and a 4.99% beneficial ownership cap for GHS.
Each put share will be priced at 92.5% of the lowest traded price over the 10 trading days before the put, and 112.5% of each put amount will be delivered in shares. Individual puts must be between $10,000 and $1,000,000, and the arrangement lasts until the earlier of 24 months after S-1 effectiveness or when GHS has purchased $3,000,000 of shares. Upon execution, NewHydrogen issued 980,713 restricted shares to GHS as commitment shares, representing 0.5% of the commitment amount, to be registered for resale under a Registration Rights Agreement.
NewHydrogen, Inc. is developing ThermoLoop™ thermochemical green hydrogen technology and remained pre-revenue in Q2 2026. For the quarter it recorded a net loss of $917,822, and a six‑month net loss of $1,740,818, driven by higher R&D of $674,387 and G&A of $861,116.
Cash declined to $739,528 at June 30, 2026, with working capital of $788,355 and a shareholders’ deficit of $2,643,279. The accumulated deficit reached $182,530,308, and management states that these conditions raise substantial doubt about continuing as a going concern within one year. The company raised $763,035 by issuing 46.4 million shares under a $3,000,000 equity purchase agreement and later issued a further 5.3 million shares in July. It continues funding a thermochemical water‑splitting research program at UC Santa Barbara, amended to total $1,690,038, while management believes existing cash will cover about four months of planned spending and that additional equity or debt financing will be required in 2026.
NewHydrogen, Inc. reported no revenue and a net loss of $822,996 for the three months ended March 31, 2026, wider than the $476,094 loss a year earlier. Operating expenses rose to $822,701, driven mainly by higher general and administrative and research and development spending.
Cash declined to $714,341 from $1,436,928 at December 31, 2025, and working capital fell to $751,663. The company has an accumulated deficit of $181,612,486 and discloses “substantial doubt” about its ability to continue as a going concern, expecting current working capital to cover roughly three months of operating expenses.
NewHydrogen relies heavily on external funding, including an equity financing agreement with GHS for up to $3,000,000, under which 63,431,529 shares had been issued as of March 31, 2026. Potential dilution is significant, with 565,000,000 stock options and 228,958,334 warrants outstanding, while common shares outstanding reached 789,554,228 as of May 15, 2026.
NewHydrogen, Inc. registers the resale of up to 171,568,471 shares of common stock by the selling stockholder under a prospectus filed on Form 424(b)(3). The Company will not receive proceeds from those resales.
The prospectus also discloses an Equity Financing Agreement with GHS Investments, LLC that permits the Company, at its discretion and subject to conditions, to sell up to $3,000,000 of common stock to GHS; 63,431,529 Purchase Shares have been sold to date for gross proceeds of $1,354,114. The GHS arrangement limits GHS ownership to 4.99% of outstanding shares and ties Purchase Price to a discount to market pricing; following an up-list the Purchase Price mechanics change and include a $5.00 floor.
NewHydrogen, Inc. filed a Post-Effective Amendment to its Form S-1 to register the resale of up to 171,568,471 shares of common stock held by GHS Investments, LLC. The company may receive up to $3,000,000 in aggregate gross proceeds under an Equity Financing Agreement with GHS; to date 63,431,529 Purchase Shares have been sold for gross proceeds of $1,354,114. The prospectus states the company will not receive proceeds from resales by GHS and that GHS is deemed an underwriter for resale purposes. The filing discloses a reported last sale price of $0.0361 per share on the OTCQB (April 24, 2026), an accumulated deficit of $180,184,490 through December 31, 2025, and a net loss of $2,846,943 for 2025. Management notes substantial doubt about the company’s ability to continue as a going concern without additional capital.
NewHydrogen, Inc. is a development-stage clean energy company focused on ThermoLoop™, a thermochemical process that uses heat and water to produce low-cost green hydrogen. The company reported no revenue in 2025 and a net loss of $2.85 million, driven mainly by higher general and administrative, research and development, and marketing expenses.
Cash at year-end 2025 was $1.44 million with working capital of $1.43 million, and the firm expects existing cash to fund operations for about six months, anticipating additional capital needs in the second half of 2026. Accumulated deficit reached $180.79 million, and the auditor’s report and management both note substantial doubt about the company’s ability to continue as a going concern.
NewHydrogen has two full-time employees, 768,031,041 common shares outstanding as of March 30, 2026, and an estimated non-affiliate market value of $22.42 million. The business is pre-commercial, with no backlog or government contracts, and relies on university research partnerships and equity financing to advance its hydrogen technology.